All NAD+ certificates

NAD+ 500 mg Certificate of Analysis Batch APL-NAD500-2607-02

NAD+ 500 mg from batch APL-NAD500-2607-02 was analysed on 15 July 2026 and measured 99.03% purity by HPLC / Mass Spectrometry, passing all 5 release tests.

Purity
99.03%
Result
All 5 tests passed
Tested
15 July 2026
Method
HPLC / Mass Spectrometry
Net content
506.8 mg

Independent verification

NAD+ 500 mg is independently tested for bacterial endotoxin by Ozcanium Analytics, an independent Australian laboratory: below 15.0 EU per vial by kinetic chromogenic LAL, analysed 30 August 2026 on lot APL-NAD500-2608-01, verification code OZ-ENDOTX-TAU3.

Issued by Ozcanium Analytics. Covers every vial size of this compound; each report opens as the laboratory issued it.

Enter a code in the Ozcanium Analytics verification portal (opens in a new tab) to confirm the report against their own records.

The certificate as issued is reproduced below — pinch to zoom on a phone, or use Print / Save as PDF for a full-size copy.

Australian Peptide Labs

In-House Analytical Laboratory

Australian Peptide Labs Pty Ltd

ABN 55 696 074 361

australianpeptidelabs.com.au

Page 1 of 2

Certificate of Analysis NAD+ 500 mg Batch APL-NAD500-2607-02
Compound
NAD+
Lot Number
APL-NAD500-2607-02
Analysis Date
15 July 2026
Method
HPLC / Mass Spectrometry
Purity
99.03%
Net Content
506.8 mg
NAD+ vial
CAS Number
53-84-9
Formula
C21H27N7O14P2
Molecular Weight
663.43 g/mol
Form
Lyophilised Powder
Manufactured
July 2026
Issued
16 July 2026
Document ID
APL-COA-NAD500-2607-02
Verification Code
Batch traceable

High Performance Liquid Chromatography (HPLC-UV) Chromatogram

mAUPDA 214 nm025050075010000.50.811.31.51.822.32.5 min 0.9431.157NAD+1.4622.097

Main peak integrated at 99.03% of total area; no single impurity peak exceeds 0.38%.

Peak List

Peaks detected: 4
#Time (min)Area% AreaIdentification
10.94323,4360.350—
21.1576,645,36599.030NAD+
31.46225,2230.380—
42.09716,1600.240—

Analytical Results

TestSpecificationResultStatus
AppearanceWhite/Off-White Lyophilised PowderConformsPASS
Identity (MS)ConfirmedConfirmedPASS
Purity (HPLC)≥98.0%99.03%PASS
Assay (HPLC)98.0–102.0%98.1%PASS
Endotoxins<0.5 EU/mg<0.15 EU/mgPASS

Australian Peptide Labs

In-House Analytical Laboratory

Australian Peptide Labs Pty Ltd

ABN 55 696 074 361

australianpeptidelabs.com.au

Page 2 of 2

NAD+ 500 mg

CAS Number: 53-84-9

Liquid Chromatography Mass Spectrometry (LC-MS) Identity Analysis

Identity confirmation with SIM

Analysis date: 15 July 2026
Monitored (m/z)Detected (m/z)Relative Intensity
664664.472.41
686686.421.18

Detection assignment: NAD+

Collected Mass Spectrum

Intensity ×107

01233004005006007008009001000 m/z 664686

Verification Protocol

  • Identity confirmed by mass spectrometry against the expected ion channels.
  • Purity measured by HPLC as peak area against all integrated impurity peaks.
  • Batch traceability: this document reports the lot number printed on the vial.
  • Analysis performed in-house by Australian Peptide Labs.

Supplied for laboratory research use only. Not a therapeutic good; not for human or veterinary use.

View NAD+ in the catalogueHow to read this certificate